A detailed history of Emerald Advisers, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, Emerald Advisers, LLC holds 27,265 shares of MDGL stock, worth $9.47 Million. This represents 0.24% of its overall portfolio holdings.

Number of Shares
27,265
Previous 96,764 71.82%
Holding current value
$9.47 Million
Previous $27.1 Million 78.66%
% of portfolio
0.24%
Previous 1.22%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 29, 2024

SELL
$212.22 - $292.96 $14.7 Million - $20.4 Million
-69,499 Reduced 71.82%
27,265 $5.79 Million
Q2 2024

Aug 06, 2024

SELL
$193.33 - $291.99 $939,390 - $1.42 Million
-4,859 Reduced 4.78%
96,764 $27.1 Million
Q1 2024

May 08, 2024

BUY
$171.37 - $283.23 $9.24 Million - $15.3 Million
53,901 Added 112.95%
101,623 $27.1 Million
Q4 2023

Feb 05, 2024

BUY
$120.4 - $237.13 $5.64 Million - $11.1 Million
46,844 Added 5335.31%
47,722 $11 Million
Q3 2023

Oct 26, 2023

SELL
$146.04 - $225.78 $8.85 Million - $13.7 Million
-60,605 Reduced 98.57%
878 $128,000
Q2 2023

Jul 25, 2023

SELL
$203.88 - $312.0 $4.2 Million - $6.42 Million
-20,581 Reduced 25.08%
61,483 $14.2 Million
Q1 2023

May 04, 2023

BUY
$231.06 - $307.08 $16 Million - $21.2 Million
69,076 Added 531.84%
82,064 $19.9 Million
Q4 2022

Feb 03, 2023

BUY
$58.39 - $296.54 $758,369 - $3.85 Million
12,988 New
12,988 $3.77 Million

Others Institutions Holding MDGL

About MADRIGAL PHARMACEUTICALS, INC.


  • Ticker MDGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,103,400
  • Market Cap $5.94B
  • Description
  • Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...
More about MDGL
Track This Portfolio

Track Emerald Advisers, LLC Portfolio

Follow Emerald Advisers, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Emerald Advisers, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Emerald Advisers, LLC with notifications on news.